Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.51 - $41.31
Previous CloseN/A
Volume154.73K
Average Volume (3M)812.30K
Market Cap
$512.72M
Enterprise Value$904.86M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Feb 27, 2025EPS Estimate
-1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.07
Shares Outstanding30,428,682
10 Day Avg. Volume848,647
30 Day Avg. Volume812,305
Standard Deviation0.21
R-Squared0.00001
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.97
Price to Cash Flow (P/CF)-12.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit61.22
Enterprise Value/Ebitda-7.20
Forecast
1Y Price Target
$31.00Price Target Upside92.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
AnaptysBio News
PremiumCompany Announcements
AnaptysBio Partners with Vanda for Imsidolimab Development
---
Bulls Say, Bears Say
Bulls Say
Financial PositionAnaptysBio is financially positioned to advance its pipeline with anticipated year-end 2024 cash of approximately $415 million, sufficient to extend its runway through year-end 2027.
Licensing AgreementAnaptysBio and Vanda Pharmaceuticals have entered into a global licensing agreement for the development and commercialization of imsidolimab, potentially opening new revenue streams.
Rosnilimab DevelopmentRosnilimab remains a key asset in Phase 2b development with important events in 2025, including top-line data from a trial in moderate-to-severe rheumatoid arthritis, suggesting potential growth opportunities.
Bears Say
Negative Market SentimentSentiment on ANAB shares is clearly negative, post ANB032 failure/discontinuation in atopic dermatitis and Lilly’s peresolimab discontinuation.
Program DiscontinuationThe price target for AnaptysBio's stock has been lowered from $45 to $32 following the discontinuation of the BTLA agonist program, reflecting potential challenges in achieving projected growth.
Trial FailureANAB announced that the Ph. IIb trial of ANB032 did not meet the primary EASI-75 endpoint nor any secondary endpoints and will discontinue further development, casting doubt on future outcomes.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.51 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $512.72M.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Feb 27, 2025 which is in 20 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Nov 05, 2024. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.647 by $0.507.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -1.62.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 30,428,682 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.647. Following the earnings report the stock price went up 11.72%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
---
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.00 (92.79% Upside)
$31.00 (92.79% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 399.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.84%
12-Months-Change
Fundamentals
Return on Equity
-196.35%
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
ANAB Stock 12 Month Forecast
Average Price Target
$31.00
▲(92.79% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
-29.66%
reiterated a buy rating 2 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of -29.66% per trade.
---